Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tissue Transplantation01:24

Tissue Transplantation

1.4K
Tissue transplantation is a significant medical procedure involving the transfer of cells, tissues, or organs from a donor to a recipient, with the primary aim of restoring lost functions. This procedure is crucial in treating a broad spectrum of diseases, including kidney diseases, liver failure, heart disease, and certain types of cancers.
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...
1.4K
Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

2.9K
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
2.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Donor-Specific Transplant Outcomes from BMTCTN 1702: A Multi-Center Prospective Biological-Assignment Trial.

Blood advances·2026
Same author

Rapid HHV-6 Clearance Following Preemptive Short-Course Foscarnet in Allogeneic Stem Cell Transplant Recipients.

American journal of hematology·2026
Same author

Impact of Stem Cell Mobilization with Chemotherapy Versus G-CSF Alone for Multiple Myeloma Patients with Suboptimal Response Before Autologous Stem Cell Transplant.

Clinical lymphoma, myeloma & leukemia·2026
Same author

Efficacy of CD19 CAR T-cell therapy for patients with B-cell acute lymphoblastic leukemia relapsed after allogeneic transplantation.

Leukemia & lymphoma·2026
Same author

Donor Search and Selection Strategy to Facilitate Comparable Transplant Rates across Donor Search Prognosis Groups: A Report from the BMT CTN 1702 Trial.

Transplantation and cellular therapy·2026
Same author

Autologous Stem Cell Transplantation for Multiple Sclerosis.

Transplantation and cellular therapy·2026

Related Experiment Video

Updated: Apr 22, 2026

Personalized Peptide Arrays for Detection of HLA Alloantibodies in Organ Transplantation
08:07

Personalized Peptide Arrays for Detection of HLA Alloantibodies in Organ Transplantation

Published on: September 6, 2017

9.8K

"No donor"? Consider a haploidentical transplant.

Stefan O Ciurea1, Ulas D Bayraktar1

  • 1Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Blood Reviews
|October 14, 2014
PubMed
Summary
This summary is machine-generated.

Haploidentical stem cell transplantation (HaploSCT) offers a faster, cheaper alternative for patients needing a transplant without an HLA-matched donor. Newer methods, like post-transplant cyclophosphamide, significantly improve outcomes and reduce mortality.

Keywords:
Alpha-beta T cell depletionCellular therapyGraft engineeringHaploidentical transplantationPost-transplantation cyclophosphamide

More Related Videos

Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade
11:55

Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade

Published on: March 14, 2011

17.2K
Orthotopic Hind Limb Transplantation in the Mouse
07:15

Orthotopic Hind Limb Transplantation in the Mouse

Published on: February 12, 2016

11.6K

Related Experiment Videos

Last Updated: Apr 22, 2026

Personalized Peptide Arrays for Detection of HLA Alloantibodies in Organ Transplantation
08:07

Personalized Peptide Arrays for Detection of HLA Alloantibodies in Organ Transplantation

Published on: September 6, 2017

9.8K
Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade
11:55

Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade

Published on: March 14, 2011

17.2K
Orthotopic Hind Limb Transplantation in the Mouse
07:15

Orthotopic Hind Limb Transplantation in the Mouse

Published on: February 12, 2016

11.6K

Area of Science:

  • Hematology
  • Immunology
  • Transplantation Medicine

Background:

  • Haploidentical stem cell transplantation (HaploSCT) is crucial for patients lacking HLA-matched donors.
  • Historically, HLA incompatibility posed a major challenge, with T-cell depletion leading to high mortality.
  • Recent advancements have improved HaploSCT outcomes and expanded its applicability.

Purpose of the Study:

  • To review current strategies for HaploSCT, focusing on controlling alloreactivity.
  • To discuss advancements in graft manipulation and GVHD prevention.
  • To explore post-transplantation therapies for relapse prevention and immune reconstitution.

Main Methods:

  • Review of recent literature on HaploSCT techniques.
  • Analysis of strategies for T-cell depletion and GVHD prophylaxis.
  • Discussion of post-transplant therapies for relapse and immunologic recovery.

Main Results:

  • Newer methods, including selective T-cell depletion and post-transplant cyclophosphamide, have dramatically improved outcomes.
  • Post-transplant cyclophosphamide is highly effective in preventing GVHD with reduced infectious complications and mortality (as low as 7% at 1 year).
  • These advancements are establishing new standards for HaploSCT.

Conclusions:

  • HaploSCT is becoming a more accessible and safer option for a wider patient population.
  • Effective control of alloreactivity and GVHD is key to successful HaploSCT.
  • Continued research into post-transplant therapies is vital for optimizing long-term outcomes and immune reconstitution.